Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | F10 | P00742 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30099037 | 0.88 | SMPD1 (0.56) | SMPD1ALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL11213011 | 0.88 | KMT2A (0.69) | SMPD1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30938023 | 0.86 | PARP1 (0.65) | SMPD1KMT2AF10 | |
| SCHEMBL202628 | 0.86 | PARP1 (0.65) | SMPD1KMT2AF10 | |
| SCHEMBL385706 | 0.86 | RAB9A (0.59) | SMPD1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28294885 | 0.85 | L3MBTL1 (0.57) | SMPD1ALDH1A1KDM4ELMNAKMT2A | |
| SCHEMBL1665041 | 0.84 | KMT2A (0.73) | SMPD1KMT2ANR1H4 | |
| SCHEMBL1665037 | 0.84 | KMT2A (0.55) | SMPD1ALDH1A1KDM4ELMNAKMT2A | |
| SCHEMBL30517635 | 0.84 | KMT2A (0.73) | SMPD1KMT2ANR1H4 | |
| SCHEMBL6154011 | 0.84 | SMN1; SMN2 (0.65) | ALDH1A1NPC1RAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10865215-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20200223867-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2020-07-16 | — | — | US | disclosed |
| US-10570153-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2019067864-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-04 | — | — | WO | disclosed |
| US-9957281-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957281-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170022221-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2017-01-26 | — | — | US | disclosed |
| US-20090252013-A1 | HYDRAZIDE CHELATE COMPLEX COMPOUND, OPTICAL RECORDING MEDIUM USING THE COMPOUND AND RECORDING METHOD THEREOF | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-10-08 | — | — | US | disclosed |
| EP-2050794-A1 | HYDRAZIDE CHELATE COMPLEX COMPOUND, OPTICAL RECORDING MEDIUM USING THE COMPOUND AND RECORDING METHOD THEREOF | Mitsubishi Chemical Corporation (JP) | 2009-04-22 | — | — | EP | disclosed |
| CN-101356241-A | Hydrazide chelate complex, optical recording medium using the same, and recording method thereof | MITSUBISHI CHEM CORP (JP) | 2009-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10865215-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | SMPD1 751/4885ALDH1A1 621/4885KDM4E 1198/4885 |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | SERPINB1, FURIN, HIF1AN | SMPD1 13/4885ALDH1A1 3562/4885KDM4E 3876/4885 |
| US-10570153-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | SMPD1 751/4885ALDH1A1 621/4885KDM4E 1198/4885 |
| US-20170022221-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | GABRA5, GABRA1, GABBR2 | SMPD1 751/4885ALDH1A1 621/4885KDM4E 1198/4885 |
| US-20090252013-A1 | HYDRAZIDE CHELATE COMPLEX COMPOUND, OPTICAL RECORDING MEDIUM USING THE COMPOUND AND RECORDING METHOD THEREOF | KCNN2, KCNH2, KCNN1 | SMPD1 4734/4885ALDH1A1 1012/4885KDM4E 748/4885 |
| US-20200223867-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | GABRA5, GABRA1, GABBR2 | SMPD1 751/4885ALDH1A1 621/4885KDM4E 1198/4885 |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | SERPINB1, FURIN, HIF1AN | SMPD1 13/4885ALDH1A1 3562/4885KDM4E 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.